Table 1 Characteristics of the included studies and outcome events

Lipton et al

2023 [22]

Lancet Neurol

USA

Randomized controlled trial

90

Zavegepant: 10 mg zavegepant;

Control: 10 mg placebo

Zavegepant (n = 623)

Control (n = 646)

Zavegepant: 81

Control: 85

Zavegepant: 40.9(13.19)

Control: 40.7(13.46)

a; b; c; d; e; f; g; h; i; j; k

Croop et al

2022 [23]

Headache

USA

Randomized controlled trial

82

Zavegepant: 10 mg zavegepant;

Control: 10 mg placebo

Zavegepant (n = 391)

Control (n = 402)

Zavegepant: 85.2

Control: 84.3

Zavegepant: 41.4 (12.9) Control: 39.9 (12.0)

a; b; c; d; e; f; g; h; i; j; k

Cady et al

2022 [24]

The Journal of Headache and Pain

USA; Denmark

Randomized controlled trial

57

Eptinezumab: 100 mg eptinezumab;

Control: 100 mg placebo

Eptinezumab (n = 238)

Control (n = 242)

Eptinezumab: 84.9

Control: 83.1

Eptinezumab: 44.9(11.99)

Control: 44.1(12.12)

a; b

Hutchinson et al. 2021 [25]

Neurology and Therapy

USA

Randomized controlled trial

188

Ubrogepant: 50 mg ubrogepant

Control: 50 mg placebo

Ubrogepant (n = 887)

Control (n = 912)

Ubrogepant: 90.5

Control: 88.7

Ubrogepant: 40.4 (12.1)

Control: 41.1 (11.9)

a; b; c; d; e; f; g; h; i; j; k

Dodick et al

2019 [26]

The New England Journal of Medicine

USA

Randomized controlled trial

89

Ubrogepant: 50 mg ubrogepant

Control: 50 mg placebo

Ubrogepant (n = 466)

Control (n = 485)

Ubrogepant: 89.7

Control: 88.7

Ubrogepant: 40.1(11.7)

Control: 40.9(11.7)

a; b; c; d; e; f; h; i; j; k

Lipton et al

2019 [27]

JAMA

USA

Randomized controlled trial

99

Ubrogepant: 50 mg ubrogepant

Control: 50 mg placebo

Ubrogepant (n = 488)

Control (n = 499)

Ubrogepant: 91.0

Control: 88.6

Ubrogepant: 41.2(12.5)

Control: 41.7(12.1)

a; b; c; d; e; f; h; i; j; k

Croop et al

2019 [28]

The Lancet

USA

Randomized controlled trial

69

Rimegepant: 75 mg Rimegepant

Control: 75 mg placebo

Rimegepant (n = 669)

Control (n = 682)

Rimegepant: 85

Control: 85

Rimegepant: 40.3 (12.1)

Control: 40.0 (11.9)

a; b; c; d; e; f; g; h; i; j; k

Lipton et al

2019 [29]

The New England Journal of Medicine

USA

Randomized controlled trial

49

Rimegepant: 75 mg Rimegepant

Control: 75 mg placebo

Rimegepant (n = 537)

Control (n = 535)

Rimegepant: 89.2

Control: 88.2

Rimegepant: 40.2 (11.9)

Control: 40.9(12.1)

a; b; c; d; e; f; g; h; i; j; k

Voss et al

2016 [30]

Cephalalgia

USA

Randomized controlled trial

55

Ubrogepant: 50 mg ubrogepant

Control: 50 mg placebo

Ubrogepant (n = 106)

Control (n = 113)

Ubrogepant: 86.8

Control: 87.6

Ubrogepant: 40.7(12.3)

Control: 40.5(11.7)

a; b; c; d; e; f; g; h; i; j; k

Marcus et al

2014 [31]

Cephalalgia

USA

Randomized controlled trial

41

Rimegepant: 75 mg Rimegepant

Control: 75 mg placebo

Rimegepant (n = 91)

Control (n = 229)

Rimegepant: 89

Control: 86

Rimegepant: 38.5 (11.87)

Control: 37.9 (11.36)

a; b; c; d; e; f; g; h; i; j; k

Hewitt et al

2011 [32]

Cephalalgia

USA

Randomized controlled trial

47

MK-3207: 200 mg MK-3207

Control: 200 mg placebo

MK-3207(n = 63)

Control (n = 140)

MK-3207: 85.7

Control: 89.3

MK-3207: 40.5 (10.7)

Control: 42.1 (11.2)

a; c; d; e; j; k

Diener et al

2010 [33]

Cephalalgia

Europe

Randomized controlled trial

47

BI 44370 TA: 400 mg BI 44370 TA

Control: 400 mg placebo

BI 44370 TA (n = 73)

Control (n = 70)

BI 44370 TA: 75.3

Control: 87.1

BI 44370 TA: 41.1 (10.0)

Control: 38.2 (10.3)

a; c; d; e; f; g; h; i; j

Connor et al

2009 [34]

Neurology

USA

Randomized controlled trial

83

Telcagepant: 300 mg telcagepant

Control: 300 mg placebo

Telcagepant (n = 371)

Control (n = 365)

Telcagepant: 86.3

Control: 87.1

Telcagepant: 41.8 (11.6)

Control: 41.9 (11.9)

a; c; d; h; i; j; k

Ho et al. 2008 [35]

The Lancet

USA; Europe

Randomized controlled trial

81

Telcagepant: 300 mg telcagepant

Control: 300 mg placebo

Telcagepant (n = 354)

Control (n = 348)

Telcagepant: 85

Control: 84

Telcagepant: 42.6 (11.4)

Control: 42.3 (12)

a; c; d; h; i; j; k

Ho et al. 2007 [36]

Neurology

USA

Randomized controlled trial

20

Telcagepant: 300 mg telcagepant

Control: 300 mg placebo

Telcagepant (n = 39)

Control (n = 115)

Telcagepant: 87.2

Control: 90.4

Telcagepant: 40.5(NR)

Control: 42.2 (NR)

a; c; d; h; i; j; k